BOSTON SCIENTIFIC CORP (1BSX.MI) Stock Fundamental Analysis
Europe - Euronext Milan - BIT:1BSX - US1011371077 - Common Stock
81.4 EUR
-0.2 (-0.25%)
Overall 1BSX gets a fundamental rating of 5 out of 10. We evaluated 1BSX against 65 industry peers in the Health Care Equipment & Supplies industry. 1BSX scores excellent on profitability, but there are some minor concerns on its financial health. 1BSX is valued quite expensive, but it does show an excellent growth.
1. Profitability
1.1 Basic Checks
1BSX had positive earnings in the past year.
In the past year 1BSX had a positive cash flow from operations.
Of the past 5 years 1BSX 4 years were profitable.
Each year in the past 5 years 1BSX had a positive operating cash flow.
1.2 Ratios
1BSX's Return On Assets of 6.54% is fine compared to the rest of the industry. 1BSX outperforms 72.31% of its industry peers.
1BSX has a Return On Equity of 11.93%. This is in the better half of the industry: 1BSX outperforms 70.77% of its industry peers.
1BSX has a Return On Invested Capital of 8.09%. This is in the better half of the industry: 1BSX outperforms 70.77% of its industry peers.
The Average Return On Invested Capital over the past 3 years for 1BSX is below the industry average of 9.71%.
The 3 year average ROIC (6.59%) for 1BSX is below the current ROIC(8.09%), indicating increased profibility in the last year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 6.54% | ||
| ROE | 11.93% | ||
| ROIC | 8.09% |
ROA(3y)3.72%
ROA(5y)2.77%
ROE(3y)6.77%
ROE(5y)5.1%
ROIC(3y)6.59%
ROIC(5y)5.7%
1.3 Margins
The Profit Margin of 1BSX (14.42%) is better than 83.08% of its industry peers.
In the last couple of years the Profit Margin of 1BSX has declined.
1BSX has a better Operating Margin (19.40%) than 83.08% of its industry peers.
In the last couple of years the Operating Margin of 1BSX has remained more or less at the same level.
The Gross Margin of 1BSX (68.57%) is better than 76.92% of its industry peers.
In the last couple of years the Gross Margin of 1BSX has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 19.4% | ||
| PM (TTM) | 14.42% | ||
| GM | 68.57% |
OM growth 3Y0.91%
OM growth 5Y1.48%
PM growth 3Y10.12%
PM growth 5Y-24.05%
GM growth 3Y-0.15%
GM growth 5Y-0.56%
2. Health
2.1 Basic Checks
1BSX has a Return on Invested Capital (ROIC), which is below the Cost of Capital (WACC), which means it is destroying value.
Compared to 1 year ago, 1BSX has more shares outstanding
1BSX has more shares outstanding than it did 5 years ago.
The debt/assets ratio for 1BSX is higher compared to a year ago.
2.2 Solvency
1BSX has an Altman-Z score of 5.40. This indicates that 1BSX is financially healthy and has little risk of bankruptcy at the moment.
With an excellent Altman-Z score value of 5.40, 1BSX belongs to the best of the industry, outperforming 86.15% of the companies in the same industry.
The Debt to FCF ratio of 1BSX is 3.03, which is a good value as it means it would take 1BSX, 3.03 years of fcf income to pay off all of its debts.
1BSX has a Debt to FCF ratio of 3.03. This is in the better half of the industry: 1BSX outperforms 73.85% of its industry peers.
1BSX has a Debt/Equity ratio of 0.48. This is a healthy value indicating a solid balance between debt and equity.
Looking at the Debt to Equity ratio, with a value of 0.48, 1BSX is in line with its industry, outperforming 47.69% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.48 | ||
| Debt/FCF | 3.03 | ||
| Altman-Z | 5.4 |
ROIC/WACC0.97
WACC8.3%
2.3 Liquidity
1BSX has a Current Ratio of 1.51. This is a normal value and indicates that 1BSX is financially healthy and should not expect problems in meeting its short term obligations.
Looking at the Current ratio, with a value of 1.51, 1BSX is in line with its industry, outperforming 44.62% of the companies in the same industry.
1BSX has a Quick Ratio of 1.51. This is a bad value and indicates that 1BSX is not financially healthy enough and could expect problems in meeting its short term obligations.
1BSX has a Quick ratio of 0.96. This is in the lower half of the industry: 1BSX underperforms 60.00% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.51 | ||
| Quick Ratio | 0.96 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 25.00% over the past year.
The Earnings Per Share has been growing by 9.56% on average over the past years. This is quite good.
1BSX shows a strong growth in Revenue. In the last year, the Revenue has grown by 21.62%.
Measured over the past years, 1BSX shows a quite strong growth in Revenue. The Revenue has been growing by 9.30% on average per year.
EPS 1Y (TTM)25%
EPS 3Y15.48%
EPS 5Y9.56%
EPS Q2Q%19.05%
Revenue 1Y (TTM)21.62%
Revenue growth 3Y12.1%
Revenue growth 5Y9.3%
Sales Q2Q%20.34%
3.2 Future
Based on estimates for the next years, 1BSX will show a quite strong growth in Earnings Per Share. The EPS will grow by 15.01% on average per year.
1BSX is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 12.51% yearly.
EPS Next Y22.13%
EPS Next 2Y18.06%
EPS Next 3Y16.46%
EPS Next 5Y15.01%
Revenue Next Year20.9%
Revenue Next 2Y16.07%
Revenue Next 3Y14.17%
Revenue Next 5Y12.51%
3.3 Evolution
The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
A Price/Earnings ratio of 32.56 indicates a quite expensive valuation of 1BSX.
1BSX's Price/Earnings ratio is in line with the industry average.
Compared to an average S&P500 Price/Earnings ratio of 26.59, 1BSX is valued a bit more expensive.
A Price/Forward Earnings ratio of 27.42 indicates a quite expensive valuation of 1BSX.
1BSX's Price/Forward Earnings is on the same level as the industry average.
Compared to an average S&P500 Price/Forward Earnings ratio of 24.03, 1BSX is valued at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 32.56 | ||
| Fwd PE | 27.42 |
4.2 Price Multiples
63.08% of the companies in the same industry are cheaper than 1BSX, based on the Enterprise Value to EBITDA ratio.
1BSX's Price/Free Cash Flow ratio is in line with the industry average.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 37.2 | ||
| EV/EBITDA | 29.88 |
4.3 Compensation for Growth
1BSX's PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a correct valuation of the company.
1BSX has a very decent profitability rating, which may justify a higher PE ratio.
A more expensive valuation may be justified as 1BSX's earnings are expected to grow with 16.46% in the coming years.
PEG (NY)1.47
PEG (5Y)3.41
EPS Next 2Y18.06%
EPS Next 3Y16.46%
5. Dividend
5.1 Amount
No dividends for 1BSX!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
BIT:1BSX (12/23/2025, 7:00:00 PM)
81.4
-0.2 (-0.25%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)
Earnings (Next)
Inst Owners93.98%
Inst Owner ChangeN/A
Ins Owners0.15%
Ins Owner ChangeN/A
Market Cap120.67B
Revenue(TTM)19.35B
Net Income(TTM)2.79B
Analysts86
Price Target110.5 (35.75%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly Dividend0
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)3.27%
Min EPS beat(2)2.49%
Max EPS beat(2)4.06%
EPS beat(4)4
Avg EPS beat(4)5.68%
Min EPS beat(4)2.49%
Max EPS beat(4)10.56%
EPS beat(8)8
Avg EPS beat(8)6.15%
EPS beat(12)12
Avg EPS beat(12)5.77%
EPS beat(16)15
Avg EPS beat(16)4.37%
Revenue beat(2)2
Avg Revenue beat(2)1.69%
Min Revenue beat(2)0.96%
Max Revenue beat(2)2.43%
Revenue beat(4)4
Avg Revenue beat(4)1.6%
Min Revenue beat(4)0.96%
Max Revenue beat(4)2.43%
Revenue beat(8)8
Avg Revenue beat(8)2.16%
Revenue beat(12)11
Avg Revenue beat(12)2.08%
Revenue beat(16)13
Avg Revenue beat(16)1.61%
PT rev (1m)-0.24%
PT rev (3m)3.22%
EPS NQ rev (1m)0.01%
EPS NQ rev (3m)2.28%
EPS NY rev (1m)1.77%
EPS NY rev (3m)1.77%
Revenue NQ rev (1m)0.09%
Revenue NQ rev (3m)2.15%
Revenue NY rev (1m)0.99%
Revenue NY rev (3m)1.08%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 32.56 | ||
| Fwd PE | 27.42 | ||
| P/S | 7.35 | ||
| P/FCF | 37.2 | ||
| P/OCF | 30.75 | ||
| P/B | 6.08 | ||
| P/tB | N/A | ||
| EV/EBITDA | 29.88 |
EPS(TTM)2.5
EY3.07%
EPS(NY)2.97
Fwd EY3.65%
FCF(TTM)2.19
FCFY2.69%
OCF(TTM)2.65
OCFY3.25%
SpS11.07
BVpS13.39
TBVpS-1.13
PEG (NY)1.47
PEG (5Y)3.41
Graham Number27.44
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 6.54% | ||
| ROE | 11.93% | ||
| ROCE | 10.04% | ||
| ROIC | 8.09% | ||
| ROICexc | 8.38% | ||
| ROICexgc | 28.19% | ||
| OM | 19.4% | ||
| PM (TTM) | 14.42% | ||
| GM | 68.57% | ||
| FCFM | 19.76% |
ROA(3y)3.72%
ROA(5y)2.77%
ROE(3y)6.77%
ROE(5y)5.1%
ROIC(3y)6.59%
ROIC(5y)5.7%
ROICexc(3y)6.75%
ROICexc(5y)5.93%
ROICexgc(3y)22.84%
ROICexgc(5y)19.53%
ROCE(3y)8.18%
ROCE(5y)7.08%
ROICexgc growth 3Y9.18%
ROICexgc growth 5Y7.17%
ROICexc growth 3Y4.96%
ROICexc growth 5Y5.6%
OM growth 3Y0.91%
OM growth 5Y1.48%
PM growth 3Y10.12%
PM growth 5Y-24.05%
GM growth 3Y-0.15%
GM growth 5Y-0.56%
F-Score6
Asset Turnover0.45
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.48 | ||
| Debt/FCF | 3.03 | ||
| Debt/EBITDA | 2.18 | ||
| Cap/Depr | 59.36% | ||
| Cap/Sales | 4.14% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 90.6% | ||
| Profit Quality | 136.98% | ||
| Current Ratio | 1.51 | ||
| Quick Ratio | 0.96 | ||
| Altman-Z | 5.4 |
F-Score6
WACC8.3%
ROIC/WACC0.97
Cap/Depr(3y)57.82%
Cap/Depr(5y)54.13%
Cap/Sales(3y)4.78%
Cap/Sales(5y)4.85%
Profit Quality(3y)134.31%
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)25%
EPS 3Y15.48%
EPS 5Y9.56%
EPS Q2Q%19.05%
EPS Next Y22.13%
EPS Next 2Y18.06%
EPS Next 3Y16.46%
EPS Next 5Y15.01%
Revenue 1Y (TTM)21.62%
Revenue growth 3Y12.1%
Revenue growth 5Y9.3%
Sales Q2Q%20.34%
Revenue Next Year20.9%
Revenue Next 2Y16.07%
Revenue Next 3Y14.17%
Revenue Next 5Y12.51%
EBIT growth 1Y30.66%
EBIT growth 3Y13.12%
EBIT growth 5Y10.92%
EBIT Next Year37.61%
EBIT Next 3Y20.84%
EBIT Next 5Y17.37%
FCF growth 1Y125.15%
FCF growth 3Y26.15%
FCF growth 5Y16.61%
OCF growth 1Y96.47%
OCF growth 3Y22.44%
OCF growth 5Y13.34%
BOSTON SCIENTIFIC CORP / 1BSX.MI FAQ
What is the ChartMill fundamental rating of BOSTON SCIENTIFIC CORP (1BSX.MI) stock?
ChartMill assigns a fundamental rating of 5 / 10 to 1BSX.MI.
What is the valuation status of BOSTON SCIENTIFIC CORP (1BSX.MI) stock?
ChartMill assigns a valuation rating of 2 / 10 to BOSTON SCIENTIFIC CORP (1BSX.MI). This can be considered as Overvalued.
What is the profitability of 1BSX stock?
BOSTON SCIENTIFIC CORP (1BSX.MI) has a profitability rating of 7 / 10.
What is the valuation of BOSTON SCIENTIFIC CORP based on its PE and PB ratios?
The Price/Earnings (PE) ratio for BOSTON SCIENTIFIC CORP (1BSX.MI) is 32.56 and the Price/Book (PB) ratio is 6.08.
Can you provide the financial health for 1BSX stock?
The financial health rating of BOSTON SCIENTIFIC CORP (1BSX.MI) is 4 / 10.